Cutaneous hand and foot toxicity associated with cancer chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 5, 2003, Pages 435-436

  Childress, June ^b   Lokich, Jake ^a  

^a Cancer Center of Boston   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DOCETAXEL; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; PACLITAXEL;

ARTICLE; BLISTER; CANCER CHEMOTHERAPY; DESQUAMATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG SAFETY; ERYTHEMA; HAND FOOT SYNDROME; HUMAN; ONYCHOLYSIS; PATHOPHYSIOLOGY; SKIN TOXICITY;

ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG ERUPTIONS; ERYTHEMA; FLUOROURACIL; FOOT; HAND; HUMANS; SYNDROME; TAXOIDS; TERMINOLOGY;

EID: 0141995652     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000026486.56886.18     Document Type: Article

References (6)

1. Lokich JJ, Moore C. Chemotherapy associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984;101:789-800.
2. Lokich JJ, Ahlgren J, Gullo J, et al. A prospective randomized comparison of continuous infusional 5fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-32.
3. Lokich J, Bothe A, Zipoli T, et al. Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system. J Clin Oncol 1983;1:24-8.
4. Sparano JA, Malik U, Rajdav L, et al. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 2001;19:3117-25.
5. Lokich J. Phase I clinical trial of weekly combined paclitaxel plus docetaxel in solid tumors. Cancer 2001;89:2309-14.
6. Patel JS. Pyridoxine for hand-foot syndrome. Hosp Pharm 1999;34:604-9.